The civic record
Read. Follow. Verify.Senate Hearing: FDA Progress on Biosimilar Drugs
Record date · January 1, 2017
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
This Senate subcommittee hearing reviewed the FDA's progress in implementing the regulatory framework for biosimilar drugs. The discussion focused on the scientific challenges of approving these complex medicines, which are derived from living cells, compared to traditional chemical drugs.
The FDA's approval process for directly impacts the availability and cost of complex medical treatments for patients, as these drugs are intended to be lower-cost alternatives to existing biologic medications.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
Patients
Patients may have access to alternative, potentially lower-cost versions of complex biologic treatments.
Pharmaceutical Manufacturers
Companies developing biosimilars or reference biologics must navigate the FDA's evolving regulatory and approval standards.
Key Facts
- The hearing took place on September 17, 2015, in the Dirksen Senate Office Building.
- Biologics are medicines derived from living cells, making them more complex and expensive to manufacture than traditional chemical-based drugs.
- Biosimilars (also called follow-ons) are biologic products designed to copy reference biologics (innovator drugs).
- Interchangeability is defined as the highest standard of similarity, where a biosimilar can be swapped for a reference drug.
Show all 5 facts
- Establishing biosimilarity is more complex than establishing equivalence for traditional generic drugs due to the nature of living cell-derived products.
Frequently Asked Questions
What is a biosimilar?
Why are biosimilars harder to make than regular generics?
What does 'interchangeability' mean in this context?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceFull breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Transition to Biosimilar Regulation
The hearing highlights the shift in FDA focus toward establishing a rigorous scientific framework for approving biosimilars to manage the complexity of living-cell medicines.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy20Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools